Biofrontera
Logotype for Biofrontera Inc

Biofrontera (BFRI) investor relations material

Biofrontera Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Biofrontera Inc
Q3 2026 earnings summary13 Nov, 2026

Executive summary

  • Q3 revenue rose 29.8% YoY to $9.1M; growth included $1.6M of orders pulled forward ahead of ITC-related supply restrictions.

  • FDA approved Ameluz PDT for superficial basal cell carcinoma (sBCC), the first PDT approved in the U.S. for a cancerous skin tumor.

  • CBP ruled redesigned RhodoLED XL-C outside the ITC exclusion order, restoring U.S. import and sales access for the redesigned lamp.

Financial highlights

  • Q3 revenue was $9.1M vs. $7.0M YoY; 9M revenue was $31.2M vs. $24.6M, up 26.6%.

  • Q3 net loss narrowed to $6.4M from $6.6M; 9M net loss narrowed to $11.8M from $16.2M.

  • Q3 gross profit was $6.7M vs. $4.9M; cost of revenues was $2.3M vs. $2.0M.

  • Q3 SG&A was $12.5M vs. $10.4M, reflecting higher ITC legal fees, lamp manufacturing and regulatory costs, and sales commissions; R&D was $0.5M vs. $0.9M.

  • 9M Adjusted EBITDA loss improved to $9.3M from $15.5M.

Outlook and guidance

  • Ameluz sBCC commercialization is planned from late Q4 2026 through Q1 2027; launch preparation and training are underway.

  • An sNDA to expand the actinic keratosis label to the extremities, neck, and trunk was submitted in October; the PDUFA date is August 5, 2027.

  • The 2026 minimum annual Ameluz order requirement of 80,000 tubes is on track.

  • Q4 gross margin is expected near 80%; Q4 is typically the strongest revenue quarter.

  • Remediation of affected lamps is expected to be substantially complete by the end of Q2 2027; management expects a clear sBCC reimbursement path at launch.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Biofrontera earnings date

Logotype for Biofrontera Inc
Q4 202619 Mar, 2027
Biofrontera
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Biofrontera earnings date

Logotype for Biofrontera Inc
Q4 202619 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Biofrontera Inc. is a biopharmaceutical company based in the United States, engaged in the commercialization of pharmaceutical products designed to treat dermatological conditions. The company's focus is on photodynamic therapy (PDT) and topical antibiotics. Biofrontera's product portfolio includes Ameluz, a prescription drug for the treatment of actinic keratosis, a common precancerous skin condition, when used in combination with its BF-RhodoLED lamp. Another product, Xepi, is a topical cream approved for the treatment of impetigo, a bacterial skin infection. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the Nasdaq.